Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Thoracic 6Gastrointestinal 4CNS 4Tumor-Agnostic 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Breast 1

Conditions

Low-grade Serous Ovarian Cancer 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × binimetinib × Gynecologic × Clear all
NCT01849874 2023-10-30

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Pfizer

Phase 3 Terminated
341 enrolled 15 charts
Gynecologic

Low-grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡